Clinical Trial Update: Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating immunogenicity and safety of a Beijing-produced COVID-19 vaccine in patients with hypertension and/or diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Hypertension

Drugs mentioned

• COVID-19 Vaccine (Produced in Beijing)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: COVID-19 Pneumonia | Phase 4 | Status: COMPLETED